Stereotactic irradiation of GH-secreting pituitary adenomas

G. Minniti, C. Scaringi, D. Amelio, R. Maurizi Enrici

Research output: Contribution to journalArticlepeer-review

Abstract

Radiotherapy (RT) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to prevent tumour regrowth and normalize elevated GH and IGF-I levels. It achieves tumour control and hormone normalization up to 90 and 70 of patients at 10-15 years. Despite the excellent tumour control, conventional RT is associated with a potential risk of developing late toxicity, especially hypopituitarism, and its role in the management of patients with GH-secreting pituitary adenomas remains a matter of debate. Stereotactic techniques have been developed with the aim to deliver more localized irradiation and minimize the long-term consequences of treatment, while improving its efficacy. Stereotactic irradiation can be given in a single dose as stereotactic radiosurgery (SRS) or in multiple doses as fractionated stereotactic radiotherapy (FSRT). We have reviewed the recent published literature on stereotactic techniques for GH-secreting pituitary tumors with the aim to define the efficacy and potential adverse effects of each of these techniques.

Original languageEnglish
Article number482861
JournalInternational Journal of Endocrinology
Volume2012
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Stereotactic irradiation of GH-secreting pituitary adenomas'. Together they form a unique fingerprint.

Cite this